CompletedPHASE2, PHASE3NCT02744742
G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
Studying Myelodysplastic neoplasm with increased blasts type 1
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nanfang Hospital, Southern Medical University
- Principal Investigator
- Qifa LiuNanfang Hospital, Southern Medical University
- Intervention
- Decitabine(drug)
- Enrollment
- 202 enrolled
- Eligibility
- 14-65 years · All sexes
- Timeline
- 2016 – 2021
Study locations (1)
- Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Collaborators
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Institute of Hematology & Blood Diseases Hospital, China · Peking University People's Hospital · First People's Hospital of Chenzhou · Liuzhou Workers' Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02744742 on ClinicalTrials.gov